Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma

Ueberroth, BE; Jones, JC; Bekaii-Saab, TS

Ueberroth, BE (通讯作者),5777 E Mayo Blvd, Phoenix, AZ 85054 USA.

PANCREATOLOGY, 2022; 22 (6): 741

Abstract

Background: Circulating tumor DNA (ctDNA) has emerged as a blood-based test with multiple utilities in oncology. In the past few years, multiple studi......

Full Text Link